Contrasting T2 Biosystems (NASDAQ:TTOO) and The Competition

T2 Biosystems (NASDAQ: TTOO) is one of 84 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its peers? We will compare T2 Biosystems to related companies based on the strength of its institutional ownership, analyst recommendations, earnings, dividends, profitability, risk and valuation.

Analyst Recommendations

This is a breakdown of current ratings for T2 Biosystems and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
T2 Biosystems 1 2 3 0 2.33
T2 Biosystems Competitors 172 1131 2469 89 2.64

T2 Biosystems currently has a consensus target price of $6.83, suggesting a potential upside of 60.41%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 10.25%. Given T2 Biosystems’ higher possible upside, research analysts plainly believe T2 Biosystems is more favorable than its peers.

Profitability

This table compares T2 Biosystems and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
T2 Biosystems -1,473.71% -178.83% -71.46%
T2 Biosystems Competitors -127.39% -36.85% -10.55%

Insider & Institutional Ownership

53.0% of T2 Biosystems shares are owned by institutional investors. Comparatively, 65.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 38.7% of T2 Biosystems shares are owned by insiders. Comparatively, 11.1% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares T2 Biosystems and its peers gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
T2 Biosystems $3.89 million -$49.26 million -2.17
T2 Biosystems Competitors $827.23 million $159.49 million 36.37

T2 Biosystems’ peers have higher revenue and earnings than T2 Biosystems. T2 Biosystems is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

T2 Biosystems has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, T2 Biosystems’ peers have a beta of 1.06, suggesting that their average share price is 6% more volatile than the S&P 500.

Summary

T2 Biosystems peers beat T2 Biosystems on 9 of the 12 factors compared.

T2 Biosystems Company Profile

T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company’s initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.

Receive News & Ratings for T2 Biosystems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1


Leave a Reply

 
© 2006-2017 BBNS.